243 related articles for article (PubMed ID: 25668489)
1. Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome [Corrected].
Latchney SE; Jaramillo TC; Rivera PD; Eisch AJ; Powell CM
Neurosci Lett; 2015 Mar; 591():86-92. PubMed ID: 25668489
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
3. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.
Velazquez R; Ash JA; Powers BE; Kelley CM; Strawderman M; Luscher ZI; Ginsberg SD; Mufson EJ; Strupp BJ
Neurobiol Dis; 2013 Oct; 58():92-101. PubMed ID: 23643842
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury.
Blaya MO; Bramlett HM; Naidoo J; Pieper AA; Dietrich WD
J Neurotrauma; 2014 Mar; 31(5):476-86. PubMed ID: 24070637
[TBL] [Abstract][Full Text] [Related]
5. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
[TBL] [Abstract][Full Text] [Related]
6. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
[TBL] [Abstract][Full Text] [Related]
7. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis.
Walker AK; Rivera PD; Wang Q; Chuang JC; Tran S; Osborne-Lawrence S; Estill SJ; Starwalt R; Huntington P; Morlock L; Naidoo J; Williams NS; Ready JM; Eisch AJ; Pieper AA; Zigman JM
Mol Psychiatry; 2015 Apr; 20(4):500-8. PubMed ID: 24751964
[TBL] [Abstract][Full Text] [Related]
8. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.
Bianchi P; Ciani E; Guidi S; Trazzi S; Felice D; Grossi G; Fernandez M; Giuliani A; Calzà L; Bartesaghi R
J Neurosci; 2010 Jun; 30(26):8769-79. PubMed ID: 20592198
[TBL] [Abstract][Full Text] [Related]
9. The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after ischemic stroke.
Loris ZB; Pieper AA; Dietrich WD
Exp Neurol; 2017 Apr; 290():63-73. PubMed ID: 28077334
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome.
Giacomini A; Stagni F; Trazzi S; Guidi S; Emili M; Brigham E; Ciani E; Bartesaghi R
Neurobiol Dis; 2015 Oct; 82():385-396. PubMed ID: 26254735
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome.
Clark S; Schwalbe J; Stasko MR; Yarowsky PJ; Costa AC
Exp Neurol; 2006 Jul; 200(1):256-61. PubMed ID: 16624293
[TBL] [Abstract][Full Text] [Related]
13. The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome.
Stagni F; Uguagliati B; Emili M; Giacomini A; Bartesaghi R; Guidi S
Sci Rep; 2021 Mar; 11(1):6300. PubMed ID: 33737521
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a proneurogenic, neuroprotective chemical.
Pieper AA; Xie S; Capota E; Estill SJ; Zhong J; Long JM; Becker GL; Huntington P; Goldman SE; Shen CH; Capota M; Britt JK; Kotti T; Ure K; Brat DJ; Williams NS; MacMillan KS; Naidoo J; Melito L; Hsieh J; De Brabander J; Ready JM; McKnight SL
Cell; 2010 Jul; 142(1):39-51. PubMed ID: 20603013
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Raspanti A; Giacomini A; Guidi S; Emili M; Ciani E; Giuliani A; Bighinati A; Calzà L; Magistretti J; Bartesaghi R
Neurobiol Dis; 2017 Jul; 103():11-23. PubMed ID: 28359846
[TBL] [Abstract][Full Text] [Related]
16. Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome.
Emili M; Stagni F; Salvalai ME; Uguagliati B; Giacomini A; Albac C; Potier MC; Grilli M; Bartesaghi R; Guidi S
Neurobiol Dis; 2020 Jul; 140():104874. PubMed ID: 32325119
[TBL] [Abstract][Full Text] [Related]
17. Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome.
Uguagliati B; Al-Absi AR; Stagni F; Emili M; Giacomini A; Guidi S; Nyengaard JR; Bartesaghi R
Hippocampus; 2021 Apr; 31(4):435-447. PubMed ID: 33464704
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective efficacy of P7C3 compounds in primate hippocampus.
Bauman MD; Schumann CM; Carlson EL; Taylor SL; Vázquez-Rosa E; Cintrón-Pérez CJ; Shin MK; Williams NS; Pieper AA
Transl Psychiatry; 2018 Sep; 8(1):202. PubMed ID: 30258178
[TBL] [Abstract][Full Text] [Related]
19. Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome.
Stagni F; Salvalai ME; Giacomini A; Emili M; Uguagliati B; Xia E; Grilli M; Bartesaghi R; Guidi S
Neurobiol Dis; 2019 Sep; 129():44-55. PubMed ID: 31085229
[TBL] [Abstract][Full Text] [Related]
20. Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome.
Guidi S; Bianchi P; Stagni F; Giacomini A; Emili M; Trazzi S; Ciani E; Bartesaghi R
CNS Neurol Disord Drug Targets; 2017; 16(7):812-819. PubMed ID: 27488422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
